Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Understanding triclabendazole resistance.

G P Brennan1, I Fairweather, A Trudgett

  • 1Queen's University of Belfast, Belfast, N. Ireland. g.brennan@qub.ac.uk

Experimental and Molecular Pathology
|April 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Some further insights into oxfendazole broad anthelmintic spectrum: Flukicidal efficacy at a high dose in sheep.

Veterinary parasitology·2026
Same author

Fasciola gigantica: Ultrastructure and cytochemistry of tegumental secretory activity and extracellular vesicle formation in juvenile flukes migrating in mouse liver.

Veterinary parasitology·2026
Same author

Albendazole and Clorsulon in Fasciola hepatica Control: Integrated Pharmacokinetic and Flukicidal Eficacy Assessment in Sheep.

Journal of veterinary pharmacology and therapeutics·2025
Same author

Macrocyclic lactones and ectoparasites control in livestock: Efficacy, drug resistance and therapeutic challenges.

International journal for parasitology. Drugs and drug resistance·2024
Same author

Fasciola gigantica: Ultrastructural localisation of neoblast recruitment in somatic tissues during growth and development in the hepatic parenchyma of experimentally infected mice.

Veterinary parasitology·2024
Same author

Albendazole metabolites excretion in human saliva as a biomarker to assess treatment compliance in mass drug administration (MDA) anthelmintic programs.

Scientific reports·2024
Same journal

Bacteriological profile of secondary infections following snakebite envenomation's: A systematic literature review.

Experimental and molecular pathology·2026
Same journal

3D virtual histopathology of human breast tissues using an X-ray grating interferometry micro CT system.

Experimental and molecular pathology·2026
Same journal

Pan-cancer analysis identifies GPRIN1 as a prognostic biomarker and promoter of cell proliferation in pancreatic cancer.

Experimental and molecular pathology·2026
Same journal

MicroRNAs and predicted targets in the switch from monolayered to spheroids of cholangiocarcinoma cells.

Experimental and molecular pathology·2026
Same journal

Tumor-infiltrating CD8<sup>+</sup>Ki-67<sup>+</sup> and CD8<sup>+</sup>LAG-3<sup>+</sup> T cells are associated with improved patient survival in retroperitoneal dedifferentiated liposarcomas and leiomyosarcomas.

Experimental and molecular pathology·2026
Same journal

Citalopram enhances cisplatin-induced cytotoxicity in T24 bladder cancer cells: An in vitro study.

Experimental and molecular pathology·2026
See all related articles

Triclabendazole resistance in liver flukes is a growing concern for livestock and human health. Understanding resistance mechanisms is crucial for developing new strategies against fascioliasis.

Area of Science:

  • Veterinary Parasitology
  • Drug Resistance Mechanisms
  • Molecular Biology

Background:

  • Triclabendazole (TCBZ) is the primary anthelmintic for liver fluke infections in livestock and humans.
  • Over two decades of use have led to widespread TCBZ resistance in liver fluke populations globally.
  • The reliance on TCBZ for fascioliasis treatment is threatened by emerging resistance.

Purpose of the Study:

  • To review the current understanding of TCBZ resistance mechanisms in liver flukes.
  • To explore potential strategies for managing and overcoming TCBZ resistance.
  • To highlight the urgent need for alternative treatment options.

Main Methods:

  • Literature review of studies on TCBZ resistance in Fasciola species.
  • Analysis of proposed mechanisms including target site modification, drug transport, and metabolism.

Related Experiment Videos

  • Examination of current and future therapeutic approaches.

    • Main Results:

    • TCBZ resistance has been reported in Australia, Europe (Ireland, Scotland, Wales, Spain, Netherlands).
    • Mechanisms of resistance may involve alterations in the fluke's target molecule, drug influx/efflux, or TCBZ metabolism.
    • The development of resistance poses a significant risk to effective fascioliasis control.

    Conclusions:

    • Urgent need to understand TCBZ resistance mechanisms to inform treatment strategies.
    • Alternative drugs, combination therapies, and novel compound discovery are essential.
    • Proactive management is required to mitigate the impact of TCBZ resistance on animal and human health.